Potensi Penggunaan Antagonis TRPV1(Transient Receptor Potential Vanilloid Type 1) Krim PAC-14028 Sebagai Terapi Dermatitis Atopik

Tri Rosalia Nur Sholikah, yuli Wahyu Rahmawati, Kartika Prahasanti, Nenny Triastuti

Abstract


Transient Receptor Potential Vanilloid type 1(TRPV1) adalah saluran kation nonselektif yang diaktifkan oleh berbagai rangsangan penghasil rasa sakit seperti capsaicin, perubahan pH dan panas. Diketahui kemungkinan bahwa TRPV1 berperan penting dalam terjadinya pruritus dan induksi inflamasi pada dermatitis atopik, sehingga Antagonis TRPV1 PAC-14028 dapat menjadi pilihan terapi potensial untuk pasien dermatitis atopik. Tujuan ditulisnya artikel ini untuk mengetahui potensi penggunaan antagonis TRPV1 krim PAC-14028 sebagai terapi pada dermatitis atopik. Artikel ini dibuat dengan meninjau jurnal penelitian dan artikel artikel ilmiah berdasarkan pencarian menggunakan PubMed, PMC, Google Scholar. Hasil penelitian menunjukkan Antagonis TRPV1 krim PAC-14028 dapat menekan gejala mirip dermatitis atopik dengan mempercepat pemulihan penghalang kulit. Sehingga dapat disimpulkan bahwa Krim PAC-14028 mempunyai potensi sebagai pengobatan pada dermatitis atopik.


Keywords


Atopic Dermatitis; Antagonist TRPV1; PAC-14028

Full Text:

PDF

References


de Camargo KR. Filosofia e sade Coletiva. Physis. 2010;20(3):7078.

Evina B. Clinical manifestations and diagnostic criteria of atopic dermatitis. J Major. 2015;4(4):2330.

Wirantari N, Rosita C, Prakoeswa S. Penggunaan Kalsineurin Inhibitor sebagai Imunomodulator Topikal pada Terapi Dermatitis Atopik ( Calcineurin Inhibitors as Topical Immunomodulators for Atopic Dermatitis ). J Period Dermatology Venereol. 2014;26:14652.

Sihaloho K, Indramaya M. Penelitian Retrospektif : Dermatitis Atopik pada Anak (Retrospective Study: Atopic Dermatitis in Childhood). Portal Garuda. 2015;27:1779.

Danarti R, Mada UG. Panduan Diagnosis dan Tatalaksana Dermatitis Atopik di Indonesia. 2018;(January).

Santoso, S 2011. Tinjauan Pustaka Tinjauan Pustaka. Conv Cent Di Kota Tegal. 2011;6.

Yun JW, Seo JA, Jeong YS, Bae IH, Jang WH, Lee J, et al. TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery. J Dermatol Sci [Internet]. 2011;62(1):815. Available from: http://dx.doi.org/10.1016/j.jdermsci.2010.10.014

Lee YW, Won CH, Jung K, Nam HJ, Choi G, Park YH, et al. Efficacy and safety of PAC-14028 cream a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. Br J Dermatol. 2019;180(5):10308.

Lopez Carrera YI, Al Hammadi A, Huang YH, Llamado LJ, Mahgoub E, Tallman AM. Epidemiology, Diagnosis, and Treatment of Atopic Dermatitis in the Developing Countries of Asia, Africa, Latin America, and the Middle East: A Review. Dermatol Ther (Heidelb) [Internet]. 2019;9(4):685705. Available from: https://doi.org/10.1007/s13555-019-00332-3

Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: Barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37(1):115.

Kezic S, ORegan GM, Lutter R, Jakasa I, Koster ES, Saunders S, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012;129(4):103140.

Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):8492.

Egawa G, Weninger W. Pathogenesis of atopic dermatitis: A short review. Cogent Biol [Internet]. 2015;1(1). Available from: http://dx.doi.org/10.1080/23312025.2015.1103459

Samochocki Z, Alifier M, Bodera P, Jeziorkowska R, Rosiak E, Jurkiewicz B, et al. T-regulatory cells in severe atopic dermatitis: Alterations related to cytokines and other lymphocyte subpopulations. Arch Dermatol Res. 2012;304(10):795801.

Toth BI, Bro T. TRP Channels and Pruritus. Open Pain J. 2013;6(1):6280.

Palareti G, Legnani C, Cosmi B, Antonucci E, Erba N, Poli D, et al. Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study. Int J Lab Hematol. 2016;38(1):429.

Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. J Allergy Clin Immunol [Internet]. 2014;133(2):42938. Available from: http://dx.doi.org/10.1016/j.jaci.2013.07.049

Bartolucci S, Netchiporouk E, Litvinov I V. Recent Therapeutic Advances in Pruritus Management for Atopic Dermatitis Patients: A Welcome Addition of Asivatrep to Our Arsenal of Future Topical Treatments. J Cutan Med Surg. 2019;23(5):5512.

Lim KM, Park YH. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012;35(3):3936.

Xie Z, Hu H. TRP channels as drug targets to relieve itch. Pharmaceuticals. 2018;11(4):120.

Lee KP, Koshelev M V. Upcoming topical TRPV1 anti-pruritic compounds. Dermatol Online J. 2020;26(9):15.

Park Y, Joo K, Woo B, Dong E, Yo S, Shin H, et al. Journal of Pharmaceutical and Biomedical Analysis Oral and topical pharmacokinetic studies of a novel TRPV1 antagonist , PAC-14028 in rats and minipigs using liquid chromatography / tandem mass spectrometric method. J Pharm Biomed Anal [Internet]. 2012;61:814. Available from: http://dx.doi.org/10.1016/j.jpba.2011.11.011

Gibson RA, Robertson J, Mistry H, McCallum S, Fernando D, Wyres M, et al. A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers. PLoS One. 2014;9(7):111.

Lee JH, Choi CS, Bae IH, Choi JK, Park YH, Park M. A novel, topical, nonsteroidal, TRPV1 antagonist, PAC-14028 cream improves skin barrier function and exerts anti-inflammatory action through modulating epidermal differentiation markers and suppressing Th2 cytokines in atopic dermatitis. J Dermatol Sci [Internet]. 2018;91(2):18494. Available from: https://doi.org/10.1016/j.jdermsci.2018.04.017




DOI: https://doi.org/10.30596/jph.v2i2.6598

DOI (PDF): https://doi.org/10.30596/jph.v2i2.6598.g5596

Refbacks

  • There are currently no refbacks.


Alamat Pengelola: Gedung Kampus 1 Universitas Muhammadiyah Sumatera Utara (UMSU) Lantai II, Laboratorium Farmakologi dan Terapi Fakultas Kedokteran UMSU Jalan Gedung Arca No. 53 Medan Sumatera Utara Indonesia, Kode Pos 20217.

Kontak (WA): 0812-6208-2844

E-mail: jurnalpanduhusada@umsu.ac.id